Remarkably efficient inhaled antifungal monotherapy for invasive pulmonary aspergillosis

European Respiratory Journal

Volumn 40, Issue 1, 2012, Pages 271-273

  Hilberg, Ole ^a   Andersen, Charlotte U ^b   Henning, Ole ^a   Lundby, Tim ^c   Mortensen, Jann ^c   Bendstrup, Elisabeth ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIBIOTIC AGENT; ANTIGEN; AZITHROMYCIN; C REACTIVE PROTEIN; FUNGUS ANTIGEN; GALACTOMANNAN ANTIGEN; LIVER ENZYME; METHYLPREDNISOLONE; POSACONAZOLE; STEROID; UNCLASSIFIED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AEROSOL; AGED; ASPERGILLUS FUMIGATUS; BLOOD ANALYSIS; BLURRED VISION; BREATHING PATTERN; BRONCHITIS; CASE REPORT; CAUSE OF DEATH; CHRONIC DISEASE; CONSTIPATION; DEPRESSION; DIAGNOSTIC PROCEDURE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EMPHYSEMA; ENZYME BLOOD LEVEL; FATIGUE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GRAFT DYSFUNCTION; HUMAN; KIDNEY FUNCTION; LETTER; LEUKOCYTE COUNT; LUNG ABSCESS; LUNG ASPERGILLOSIS; LUNG INFILTRATE; LUNG TRANSPLANTATION; MALE; MENINGIOMA; MONOTHERAPY; NAUSEA; NEBULIZATION; PLEURA EFFUSION; POLYNEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, INHALATION; AGED; ANTIFUNGAL AGENTS; HUMANS; MALE; PULMONARY ASPERGILLOSIS; PYRIMIDINES; TRIAZOLES;

EID: 84863495434     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00163511     Document Type: Letter

References (9)

1. Thompson GR III, Lewis JS. Pharmacology and clinical use of voriconazole. Expert Opin Drug Metab Toxicol 2010; 6: 83-94.
2. European Medicines Agency. Vfend. Summary of product characteristics. London, EMA, 2010.
3. Tolman JA, Wiederhold NP, McConville JT, et al. Inhaled voriconazole for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2009; 53: 2613-2615.
4. Tolman JA, Nelson NA, Son YJ, et al. Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. Eur J Pharm Biopharm 2009; 72: 199-205.
5. Crandon JL, Banevicius MA, Fang AF, et al. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother 2009; 53: 5102-5107.
6. Weiler S, Fiegl D, MacFarland R, et al. Human tissue distribution of voriconazole. Antimicrob Agents Chemother 2011; 55: 925-928.
7. Tolman JA, Nelson NA, Bosselmann S, et al. Dose tolerability of chronically inhaled voriconazole solution in rodents. Int J Pharm 2009; 379: 25-31.
8. Morrow PE. Conference on the scientific basis of respiratory therapy. Aerosol therapy. Aerosol characterization and deposition. Am Rev Respir Dis 1974; 110: 88-99.
9. Brand P, Friemel I, Meyer T, et al. Total deposition of therapeutic particles during spontaneous and controlled inhalations. J Pharm Sci 2000; 89: 724-731.